225 related articles for article (PubMed ID: 37252797)
1. Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations.
Zhao Z; Cao K; Watanabe J; Philips CN; Zeidner JM; Ishi Y; Wang Q; Gold SR; Junkins K; Bartom ET; Yue F; Chandel NS; Hashizume R; Ben-Sahra I; Shilatifard A
J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37252797
[TBL] [Abstract][Full Text] [Related]
2. The MLL3/MLL4 branches of the COMPASS family function as major histone H3K4 monomethylases at enhancers.
Hu D; Gao X; Morgan MA; Herz HM; Smith ER; Shilatifard A
Mol Cell Biol; 2013 Dec; 33(23):4745-54. PubMed ID: 24081332
[TBL] [Abstract][Full Text] [Related]
3. The MLL3/4 H3K4 methyltransferase complex in establishing an active enhancer landscape.
Wang LH; Aberin MAE; Wu S; Wang SP
Biochem Soc Trans; 2021 Jun; 49(3):1041-1054. PubMed ID: 34156443
[TBL] [Abstract][Full Text] [Related]
4. A small UTX stabilization domain of Trr is conserved within mammalian MLL3-4/COMPASS and is sufficient to rescue loss of viability in null animals.
Rickels R; Wang L; Iwanaszko M; Ozark PA; Morgan MA; Piunti A; Khalatyan N; Soliman SHA; Rendleman EJ; Savas JN; Smith ER; Shilatifard A
Genes Dev; 2020 Nov; 34(21-22):1493-1502. PubMed ID: 33033055
[TBL] [Abstract][Full Text] [Related]
5. Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Wang L; Zhao Z; Ozark PA; Fantini D; Marshall SA; Rendleman EJ; Cozzolino KA; Louis N; He X; Morgan MA; Takahashi YH; Collings CK; Smith ER; Ntziachristos P; Savas JN; Zou L; Hashizume R; Meeks JJ; Shilatifard A
Nat Med; 2018 Jun; 24(6):758-769. PubMed ID: 29785026
[TBL] [Abstract][Full Text] [Related]
6. Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.
Zhao Z; Aoi Y; Philips CN; Meghani KA; Gold SR; Yu Y; John LS; Qian J; Zeidner JM; Meeks JJ; Shilatifard A
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2310063120. PubMed ID: 38113256
[TBL] [Abstract][Full Text] [Related]
7. Crucial roles of mixed-lineage leukemia 3 and 4 as epigenetic switches of the hepatic circadian clock controlling bile acid homeostasis in mice.
Kim DH; Rhee JC; Yeo S; Shen R; Lee SK; Lee JW; Lee S
Hepatology; 2015 Mar; 61(3):1012-23. PubMed ID: 25346535
[TBL] [Abstract][Full Text] [Related]
8. COMPASS Ascending: Emerging clues regarding the roles of MLL3/KMT2C and MLL2/KMT2D proteins in cancer.
Fagan RJ; Dingwall AK
Cancer Lett; 2019 Aug; 458():56-65. PubMed ID: 31128216
[TBL] [Abstract][Full Text] [Related]
9. Mll3 and Mll4 Facilitate Enhancer RNA Synthesis and Transcription from Promoters Independently of H3K4 Monomethylation.
Dorighi KM; Swigut T; Henriques T; Bhanu NV; Scruggs BS; Nady N; Still CD; Garcia BA; Adelman K; Wysocka J
Mol Cell; 2017 May; 66(4):568-576.e4. PubMed ID: 28483418
[TBL] [Abstract][Full Text] [Related]
10. MLL3/MLL4/COMPASS Family on Epigenetic Regulation of Enhancer Function and Cancer.
Sze CC; Shilatifard A
Cold Spring Harb Perspect Med; 2016 Nov; 6(11):. PubMed ID: 27638352
[TBL] [Abstract][Full Text] [Related]
11. MLL3/MLL4 methyltransferase activities control early embryonic development and embryonic stem cell differentiation in a lineage-selective manner.
Xie G; Lee JE; Senft AD; Park YK; Jang Y; Chakraborty S; Thompson JJ; McKernan K; Liu C; Macfarlan TS; Rocha PP; Peng W; Ge K
Nat Genet; 2023 Apr; 55(4):693-705. PubMed ID: 37012455
[TBL] [Abstract][Full Text] [Related]
12. Enhancer malfunction in cancer.
Herz HM; Hu D; Shilatifard A
Mol Cell; 2014 Mar; 53(6):859-66. PubMed ID: 24656127
[TBL] [Abstract][Full Text] [Related]
13. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4.
Herz HM; Mohan M; Garruss AS; Liang K; Takahashi YH; Mickey K; Voets O; Verrijzer CP; Shilatifard A
Genes Dev; 2012 Dec; 26(23):2604-20. PubMed ID: 23166019
[TBL] [Abstract][Full Text] [Related]
14. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4.
Lee J; Kim DH; Lee S; Yang QH; Lee DK; Lee SK; Roeder RG; Lee JW
Proc Natl Acad Sci U S A; 2009 May; 106(21):8513-8. PubMed ID: 19433796
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53 regulates enhancer-associated H3K4 monomethylation through interactions with the methyltransferase MLL4.
Rahnamoun H; Hong J; Sun Z; Lee J; Lu H; Lauberth SM
J Biol Chem; 2018 Aug; 293(34):13234-13246. PubMed ID: 29954944
[TBL] [Abstract][Full Text] [Related]
16. Structural insights into trans-histone regulation of H3K4 methylation by unique histone H4 binding of MLL3/4.
Liu Y; Qin S; Chen TY; Lei M; Dhar SS; Ho JC; Dong A; Loppnau P; Li Y; Lee MG; Min J
Nat Commun; 2019 Jan; 10(1):36. PubMed ID: 30604749
[TBL] [Abstract][Full Text] [Related]
17. MLL4 is required after implantation, whereas MLL3 becomes essential during late gestation.
Ashokkumar D; Zhang Q; Much C; Bledau AS; Naumann R; Alexopoulou D; Dahl A; Goveas N; Fu J; Anastassiadis K; Stewart AF; Kranz A
Development; 2020 Jun; 147(12):. PubMed ID: 32439762
[TBL] [Abstract][Full Text] [Related]
18. CARM1-mediated methylation of ASXL2 impairs tumor-suppressive function of MLL3/COMPASS.
Zhao Z; Rendleman EJ; Szczepanski AP; Morgan MA; Wang L; Shilatifard A
Sci Adv; 2022 Oct; 8(40):eadd3339. PubMed ID: 36197977
[TBL] [Abstract][Full Text] [Related]
19. H3.3K4M destabilizes enhancer H3K4 methyltransferases MLL3/MLL4 and impairs adipose tissue development.
Jang Y; Broun A; Wang C; Park YK; Zhuang L; Lee JE; Froimchuk E; Liu C; Ge K
Nucleic Acids Res; 2019 Jan; 47(2):607-620. PubMed ID: 30335158
[TBL] [Abstract][Full Text] [Related]
20. Distinct kinetic mechanisms of H3K4 methylation catalyzed by MLL3 and MLL4 core complexes.
Zheng Y; Huang Y; Mencius J; Li Y; Zhao L; Luo W; Chen Y; Quan S
J Biol Chem; 2021; 296():100635. PubMed ID: 33823156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
